{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:56:39Z","timestamp":1791111399231,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,4,4]],"date-time":"2009-04-04T00:00:00Z","timestamp":1238803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00228-009-0648-1","type":"journal-article","created":{"date-parts":[[2009,4,3]],"date-time":"2009-04-03T03:53:39Z","timestamp":1238730819000},"page":"551-560","source":"Crossref","is-referenced-by-count":29,"title":["Evaluation of drug\u2013drug interactions with fesoterodine"],"prefix":"10.1007","volume":"65","author":[{"given":"Bimal","family":"Malhotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sachse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,4]]},"reference":[{"key":"648_CR1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/nau.20251","volume":"25","author":"P Abrams","year":"2006","unstructured":"Abrams P, Artibani W, Cardozo L et al (2006) Reviewing the ICS 2002 terminology report: The ongoing debate. Neurourol Urodynam 25:293","journal-title":"Neurourol Urodynam"},{"issue":"1","key":"648_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61(1):37\u201349","journal-title":"Urology"},{"issue":"3 Pt 2","key":"648_CR3","first-page":"S5","volume":"175","author":"AJ Wein","year":"2006","unstructured":"Wein AJ, Rackley RR (2006) Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol 175(3 Pt 2):S5\u2013S10","journal-title":"J Urol"},{"issue":"6","key":"648_CR4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327\u2013336","journal-title":"World J Urol"},{"issue":"6","key":"648_CR5","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306\u20131315","journal-title":"Eur Urol"},{"issue":"1","key":"648_CR6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","volume":"3","author":"K-E Andersson","year":"2004","unstructured":"Andersson K-E (2004) Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 3(1):46\u201353","journal-title":"Lancet Neurol"},{"issue":"10","key":"648_CR7","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/14656566.9.10.1787","volume":"9","author":"MC Michel","year":"2008","unstructured":"Michel MC (2008) Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 9(10):1787\u20131796","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"648_CR8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.5414\/CPP46556","volume":"46","author":"BK Malhotra","year":"2008","unstructured":"Malhotra BK, Guan Z, Wood N et al (2008) Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 46(11):556\u2013563","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"22\u201323","key":"648_CR9","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0024-3205(01)01051-7","volume":"68","author":"L Nilvebrant","year":"2001","unstructured":"Nilvebrant L (2001) Clinical experiences with tolterodine. Life Sci 68(22\u201323):2549\u20132556","journal-title":"Life Sci"},{"issue":"7","key":"648_CR10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1358\/dof.2004.029.07.854168","volume":"29","author":"P Cole","year":"2004","unstructured":"Cole P (2004) Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future 29(7):715\u2013720","journal-title":"Drugs Future"},{"key":"648_CR11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1146\/annurev.pharmtox.41.1.815","volume":"41","author":"HG Xie","year":"2001","unstructured":"Xie HG, Kim RB, Wood AJ et al (2001) Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41:815\u2013850","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"648_CR12","volume-title":"Full prescribing information","author":"Toviaz (fesoterodine fumarate)","year":"2007","unstructured":"Toviaz (fesoterodine fumarate) (2007) Full prescribing information. Pfizer, New York"},{"issue":"5","key":"648_CR13","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/00000539-200211000-00038","volume":"95","author":"PJ Davis","year":"2002","unstructured":"Davis PJ, Stiller RL, Wilson AS et al (2002) In vitro remifentanil metabolism: the effects of whole blood constituents and plasma butyrylcholinesterase. Anesth Analg 95(5):1305\u20131307 (table of contents)","journal-title":"Anesth Analg"},{"issue":"4 Suppl","key":"648_CR14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00000539-199910001-00001","volume":"89","author":"CE Rosow","year":"1999","unstructured":"Rosow CE (1999) An overview of remifentanil. Anesth Analg 89[4 Suppl]:S1\u2013S3","journal-title":"Anesth Analg"},{"issue":"15","key":"648_CR15","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2165\/00023210-200418150-00004","volume":"18","author":"R Beers","year":"2004","unstructured":"Beers R, Camporesi E (2004) Remifentanil update: clinical science and utility. CNS Drugs 18(15):1085\u20131104","journal-title":"CNS Drugs"},{"issue":"6","key":"648_CR16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.clpt.2004.08.007","volume":"76","author":"V Charasson","year":"2004","unstructured":"Charasson V, Bellott R, Meynard D et al (2004) Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76(6):528\u2013535","journal-title":"Clin Pharmacol Ther"},{"key":"648_CR17","volume-title":"Harrison\u2019s principles of internal medicine","author":"AS Fauci","year":"2008","unstructured":"Fauci AS, Braunwald E, Kasper DL et al (2008) Harrison\u2019s principles of internal medicine, 17th edn. McGraw-Hill, New York","edition":"17"},{"issue":"4","key":"648_CR18","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1046\/j.1365-2125.1999.00053.x","volume":"48","author":"N Brynne","year":"1999","unstructured":"Brynne N, Forslund C, Hallen B et al (1999) Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 48(4):564\u2013572","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"648_CR19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/jac\/37.6.1111","volume":"37","author":"F Oesch","year":"1996","unstructured":"Oesch F, Arand M, Benedetti MS et al (1996) Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother 37(6):1111\u20131119","journal-title":"J Antimicrob Chemother"},{"key":"648_CR20","volume-title":"Harrison\u2019s principles of internal medicine","author":"DL Kasper","year":"2004","unstructured":"Kasper DL, Braunwald E, Hauser S et al (2004) Harrison\u2019s principles of internal medicine, 16th edn. McGraw-Hill, New York","edition":"16"},{"issue":"11","key":"648_CR21","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0149-2918(00)89083-9","volume":"23","author":"B Olsson","year":"2001","unstructured":"Olsson B, Landgren BM (2001) The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Clin Ther 23(11):1876\u20131888","journal-title":"Clin Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0648-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0648-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0648-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T08:50:43Z","timestamp":1589705443000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0648-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,4]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0648-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,4]]}}}